They observed that the HDRT + LDRT + ICIs group showed slower primary and secondary tumor growth, higher levels of immune effector cell infiltration, and a greater reduction of transforming growth factor beta (TGF-β) at secondary sites than mice that were receiving HDRT or LDRT alone or in combination with immunotherapy [19]. This evidence concerns the gene TGFB1 and neoplasm.